InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025
NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of ifebemtinib (IN10018), an oral focal adhesion kinase (FAK) inhibitor in combination with garsorasib (D-1533), an oral KRAS G12C inhibitor, in KRAS G12C mutant solid...
‘Sustainable CDMO’ Samsung Biologics releases 2022 ESG Report
Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. Details new social contribution activities that strives to support the health of its local communities. Requires commitment to the Supplier Code of Conduct, enhanced in accordance with RBA and PSCI. Establishes increased independence and transparency in its...
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; The China new drug application submission is expected in Q2 2024, while ex-China product development is in active progress. SHANGHAI,...
Triastek and Siemens announce strategic collaboration to accelerate digital transformation of the pharmaceutical industry
NANJING, China, March 17, 2022 /PRNewswire/ -- Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's industry-leading 3D printing and digital pharmaceutical technologies and Siemens' global leadership in automation and digitization is expected to lead to innovative...
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors
SHANGHAI, Aug. 7, 2023 /PRNewswire/ -- Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate ("ADC") therapeutics to treat patients with cancer and autoimmune diseases, today announced that the company has expanded its collaboration with BioNTech SE to develop, manufacture and commercialize...
Global Times: China’s medical assistance boosts healthcare development in South Pacific region
BEIJING, Sept. 18, 2023 /PRNewswire/ -- "For this surgery, we have prepared for more than half a year," Xiao Yuehai told the Global Times when talking about the first laparoscopic surgery carried out in Solomon Islands. Xiao is an urologist from the Affiliated Hospital of Guizhou Medical University (AHGMU) and a member of the second group of Chinese medical...
CRT 2023 selects Syntach Cardiac Support System for Best Innovation Competition
LUND, Sweden, Feb. 22, 2023 /PRNewswire/ -- Syntach AB ("Syntach") is pleased to announce that the Company's Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the Omni Shoreham Hotel in...
TraceLink Becomes First Solution Provider to Secure All 16 GS1 US Conformance Trustmarks for EPCIS File Support
BOSTON, Aug. 26, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, proudly announces it has become the first and only solution provider to secure all 16 GS1 US Conformance Trustmarks for EPCIS file support. These trustmarks certify that...
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
LONDON, June 29, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology could pave the way for more effective and less invasive treatment for people living with type 1...
SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health
Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. Both reviews expanded cooperation, including next-generation preventive medicines. SEONGNAM, South Korea, Aug. 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today...
